+

WO1998014587A1 - Inhibition de la replication du vih au moyen d'analogues de peptides tat solubles - Google Patents

Inhibition de la replication du vih au moyen d'analogues de peptides tat solubles Download PDF

Info

Publication number
WO1998014587A1
WO1998014587A1 PCT/US1997/017704 US9717704W WO9814587A1 WO 1998014587 A1 WO1998014587 A1 WO 1998014587A1 US 9717704 W US9717704 W US 9717704W WO 9814587 A1 WO9814587 A1 WO 9814587A1
Authority
WO
WIPO (PCT)
Prior art keywords
transdominant
xaa
amino acid
peptide
acid residue
Prior art date
Application number
PCT/US1997/017704
Other languages
English (en)
Inventor
Fatah Kashanchi
Mohamad Reza Sadaie
John N. Brady
Original Assignee
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEAL TH AND HUMAN SERVICES
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEAL TH AND HUMAN SERVICES filed Critical THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEAL TH AND HUMAN SERVICES
Priority to AU46632/97A priority Critical patent/AU4663297A/en
Priority to US09/269,991 priority patent/US6686333B1/en
Publication of WO1998014587A1 publication Critical patent/WO1998014587A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the present invention relates to nucleic acid and peptide compositions which inhibit HIV replication in a mammalian cell.
  • the present invention further relates to methods of inhibiting HIV replication in a mammalian cell by administering the compositions of the invention.
  • HIV-1 Human immunodeficiency virus type
  • LTR long terminal repeat
  • Tat's mechanism of action has been implicated to be at both transcription initiation and elongation (Kashanchi F, et al. (1994), Nature 367:295-299; Xhou Q, et al. ( 1 995), EMBO J, 14:321 -328; Chiang C-M, et al. ( 1 995), Science, 267:531 -536).
  • Tat protein has been suggested as a means to inhibit HIV replication in vivo. Since the pharmaceutical utility of transdominant mutants of minimal length is generally desired, attempts have been made to define the elements of Tat which are necessary and sufficient to inhibit Tat function. Such attempts have been discredited or implicated nearly full length regions of the Tat protein.
  • Tat structure comprises an amino-terminal domain, a cysteine-rich domain, a core region, and a basic domain.
  • the Tat core domain is a stretch of eleven amino acids between the cysteine-rich and basic domain. The core domain is conserved in all HIV isolates.
  • Kashanchi et al. (Nature, 367:295-299 (1994)) reported that the lysine at position 41 of the core was critical for transactivation in vivo.
  • Green et al. reported that Tat peptides spanning amino acids 37-62 (and including the core domain) could act as transactivators (Cell, 55: 1 1 79- 1 188 ( 1988)) .
  • Pearson et al. (Proc Nat/ Acad Sci USA, 87:5079-5083 ( 1 990)) studied peptides and mutant peptides derived from the Tat protein to determine the essential features of peptides having the inhibitory transdominant phenotype.
  • Pearson et al. further discount the findings of Green et al. , and instead teach that their mutagenesis studies suggest that both an intact amino terminus and cysteine- rich domain are required for the inhibitory transdominant phenotype.
  • the thrust of the prior art is that the inhibitory transdominant phenotype of a core domain peptide requires an intact amino terminus, as well as a cysteine-rich domain.
  • an inhibitory transdominant soluble Tat peptide of minimal length for in vitro and in vivo applications is an inhibitory transdominant soluble Tat peptide of minimal length for in vitro and in vivo applications. The present invention provides these and other advantages.
  • the present invention relates to an isolated transdominant soluble Tat peptide.
  • the transdominant soluble Tat peptide comprises a transdominant peptide sequence Cys-Phe-Xaa 39 -Xaa 40 -Xaa 41 -Gly- Leu-Gly-lle-Ser-Xaa 47 -Gly-Xaa 49 -Lys (SEQ ID NO: 1 ), wherein Xaa 39 is an amino acid residue selected from the group consisting of: Leu, Met, lie, Thr, Gin, and Val; Xaa 40 is an amino acid residue selected from the group consisting of: Thr, Arg, Lys, and Asn; Xaa 41 is an amino acid residue exclusive of Lys; Xaa 47 is an amino acid residue selected from the group consisting of: Tyr and His; Xaa 49 is an amino acid residue selected from the group consisting of: Arg and Lys.
  • the transdominant peptide sequence comprises an amino acid residue substitution at a position selected from the group consisting of: 44, 46, 47, and combinations thereof. Additionally, the transdominant soluble Tat peptide lacks an intact amino-terminal domain or an intact cysteine-rich domain. In some embodiments, the transdominant peptide sequence comprises a single amino acid residue substitution at position 44. In other embodiments, the transdominant peptide sequence comprises a single amino acid residue substitution at position 46 or 47. Generally, the transdominant soluble Tat peptide is no longer than 25 amino acid residues in length. In preferred embodiments, the amino acid at position 44 is an alanine residue. Typically, the transdominant peptide sequence is substituted only at position 44.
  • the present invention relates to an isolated nucleic acid sequence encoding a transdominant soluble Tat peptide.
  • the transdominant soluble Tat peptide comprises a transdominant peptide sequence having the sequence Cys-Phe-Xaa 39 -Xaa 40 -Xaa 41 -Gly-Leu-Gly-lle-Ser-Xaa 47 -Gly- Xaa 49 -Lys (SEQ ID NO: 1 ), wherein Xaa 39 is an amino acid residue selected from the group consisting of: Leu, Met, lie, Thr, Gin, and Val; Xaa 40 is an amino acid residue selected from the group consisting of: Thr, Arg, Lys, and Asn; Xaa 41 is an amino acid residue exclusive of Lys; Xaa 47 is an amino acid residue selected from the group consisting of: Tyr and His; Xaa 49 is an amino acid residue selected from the group consisting of: Arg and Lys.
  • the transdominant peptide sequence comprises an amino acid residue substitution at a position selected from the group consisting of: 44, 46, 47, and combinations thereof. Additionally, the transdominant soluble Tat peptide lacks an intact amino- terminal domain or an intact cysteine-rich domain. In a further aspect, the present invention is directed to an expression vector.
  • the expression vector comprises a nucleic acid encoding a transdominant soluble Tat peptide comprising a transdominant peptide sequence having the sequence Cys-Phe-Xaa 39 -Xaa 40 -Xaa 41 -Gly-Leu-Gly-lle-Ser-Xaa 47 -Gly- Xaa 49 -Lys (SEQ ID NO: 1 ), wherein Xaa 39 is an amino acid residue selected from the group consisting of: Leu, Met, lie, Thr, Gin, and Val; Xaa 40 is an amino acid residue selected from the group consisting of: Thr, Arg, Lys, and Asn; Xaa 41 is an amino acid residue exclusive of Lys; Xaa 47 is an amino acid residue selected from the group consisting of: Tyr and His; Xaa 49 is an amino acid residue selected from the group consisting of: Arg and Lys.
  • the transdominant peptide sequence comprises an amino acid residue substitution at a position selected from the group consisting of: 44, 46, 47, and combinations thereof. Additionally, the transdominant soluble Tat peptide lacks an intact amino- terminal domain or an intact cysteine-rich domain.
  • the present invention relates to a method of inhibiting HIV replication in a mammalian cell.
  • the method comprises administering a therapeutically effective amount of a transdominant soluble Tat peptide to a mammalian cell.
  • the Tat peptide comprises a nucleic acid encoding a transdominant peptide sequence having the sequence Cys-Phe-Xaa 39 -Xaa 40 - Xaa 41 -Giy-Leu-Gly-lle-Ser-Xaa 47 -Gly-Xaa 49 -Lys (SEQ ID NO: 1 ), wherein Xaa 39 is an amino acid residue selected from the group consisting of: Leu, Met, lie, Thr, Gin, and Val; Xaa 40 is an amino acid residue selected from the group consisting of: Thr, Arg, Lys, and Asn; Xaa 41 is an amino acid residue exclusive of Lys; Xaa 47 is an amino acid residue selected from the group consisting of
  • the transdominant peptide sequence comprises an amino acid residue substitution at a position selected from the group consisting of: 44, 46, 47, and combinations thereof. Additionally, the transdominant soluble Tat peptide lacks an intact amino-terminal domain or an intact cysteine-rich domain.
  • the transdominant peptide sequence comprises a single amino acid residue substitution at position 44. In other embodiments, the transdominant peptide sequence comprises a single amino acid residue substitution at position 46 or 47. Generally, the transdominant soluble Tat peptide is no longer than 25 amino acid residues in length. In preferred embodiments, the amino acid at position 44 is an alanine residue. Typically, the transdominant peptide sequence is substituted only at position 44.
  • the therapeutically effective dose is administered ex vivo, in others the therapeutically effective dose is administered in vivo.
  • the mammalian cell is a human cell.
  • administration of the therapeutically effective dose of the transdominant soluble Tat peptide comprises expressing in the cell an isolated nucleic acid encoding the soluble transdominant Tat peptide.
  • the transdominant soluble Tat peptide is itself administered.
  • Compositions and methods of the present invention have utility as therapeutic or prophylactic agent in inhibiting HIV replication. Various embodiments of this and other aspects of the invention can be had by reference to the specification as a whole. DETAILED DESCRIPTION OF THE INVENTION The present invention provides compositions and methods for inhibiting replication of HIV in vivo.
  • soluble Tat peptides having a core domain, but lacking the amino-terminal domain and/or cysteine-rich domain have the inhibitory transdominant phenotype when substitutions are made at positions 41 , and 44, 46, or 47.
  • core domain peptides lacking either the amino-terminal domain and/or cysteine rich domain can be altered to yield peptides with the transdominant phenotype.
  • These soluble Tat peptides have pharmaceutical utility as a means to control replication of HIV in vivo or ex vivo.
  • the soluble Tat peptides also have utility in regulating translation of cloned mRNA comprising a TAR sequence.
  • the peptide can be used to control synthesis of desired proteins in eukaryotic expression systems.
  • Transdominant soluble Tat peptide includes reference to a peptide of less than 300 amino acids in length which comprises a transdominant peptide sequence.
  • the transdominant soluble Tat peptide inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat. Inhibition as measured by transfection and chloramphenicol acetyl transferase (CAT) assay according to the method of Example 1 , inhibits activation by the Tat protein at least 20%, typically at least 30%, preferably at least 40% or 50%, more preferably at least 60% or 70%, and most preferably at least 80% or 90%, relative to the wild-type Tat protein.
  • CAT chloramphenicol acetyl transferase
  • Transdominant peptide sequence or “transdominant Tat peptide sequence” includes reference to a contiguous sequence derived from the Tat protein of HIV-1 . See, e.g., Pearson et al., Proc. Nat/. Acad. Sci. USA,
  • the transdominant peptide sequence comprises at least the contiguous amino acids from residue 37 through 50 substituted as provided herein.
  • amino acid residue or “amino acid residue” or “amino acid” includes reference to an amino acid that is incorporated into a protein, polypeptide, or peptide (collectively “peptide”).
  • the amino acid can be a naturally occurring amino acid and, unless otherwise limited, can encompass known analogs of natural amino acids that can function in a similar manner as naturally occurring amino acids.
  • amino acid residue exclusive of Lys includes reference to all amino acids with the exception of lysine or an analog thereof. Typically, any of the other 1 9 natural amino acids can be substituted for lysine.
  • nucleic acid includes reference to a deoxyribonucleotide or ribonucleotide polymer in either single- or double-stranded form, and unless otherwise limited, encompasses known analogues of natural nucleotides that hybridize to nucleic acids in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence includes the complementary sequence thereof.
  • encoding or “encoded”, with respect to a specified nucleic acid, includes reference to the inclusion of the information for translation into the specified protein. The information is specified by the use of codons.
  • the amino acid sequence is encoded by the nucleic acid using the "universal" genetic code.
  • variants of the universal code such as are present in some plant, animal, and fungal mitochondria, the bacterium Mycoplasma capricolum (Proc. Natl. Acad. Sci. , 82:2306-2309 ( 1 985), or the ciliate Macronucleus, can be used when the nucleic acid is expressed using these organisms.
  • expression vector includes reference to a nucleic acid construct, generated recombinantly or synthetically, with a series of specified nucleic acid elements which permit transcription of a particular nucleic acid in a host cell.
  • the expression vector can be part of a plasmid, virus, or nucleic acid fragment.
  • the expression vector includes a nucleic acid to be transcribed, and a promoter (e.g., adenovirus VA-1 promoter).
  • ⁇ ективное amount or “amount effective to” or “therapeutically effective amount” includes reference to a dosage sufficient to produce a desired result, such as inhibition of HIV-1 or HIV-2 replication.
  • ex vivo includes reference to introducing a composition into a cell which is outside the body of the organism from which a cell or cells is obtained or from which a cell line is isolated . Ex vivo transfection is preferably followed by re-infusion of the cells back into the organism. In contrast, “in vivo” includes reference to introducing a composition into a cell which is within the body of the organism from which the cell was obtained or from which a cell line is isolated .
  • intact amino-terminal domain includes reference to an amino acid sequence which, when fused to the amino terminus of a HIV-1 Tat protein lacking the amino-terminal domain (e.g., amino acid residues 1 -21 ), is able to cause transactivation of the HIV-1 LTR of at least 20%, generally at least 50%, preferably at least 70%, more preferably at least 80%, and most preferably at least 90% of the wild-type Tat protein transactivation level.
  • Transactivation of the HIV-1 LTR is conveniently assessed using a CAT assay as described herein in Example 1 , and e.g., Kashanchi et al., J. Virol. , 68(5) :3298- 3307 ( 1994); Pearson et al., Proc. Natl.
  • Jurkat cells (ATCC CRL-81 63) are conveniently employed in transactivation assays.
  • intact cysteine-rich domain includes reference to an amino acid sequence which, when fused into a deleted cysteine-rich domain (e.g., amino acid residues 21 -37) of a HIV-1 Tat protein, is able to cause transactivation of the HIV-1 LTR of at least 20%, generally at least 50%, preferably at least 70%, more preferably at least 80%, and most preferably at least 90% of the wild-type Tat protein transactivation level.
  • isolated or “biologically pure” include reference to material which is substantially or essentially free from components which normally accompany or interact with it as found in its naturally occurring environment.
  • isolated material optionally comprises material not found with the material in its natural environment.
  • operably linked refers to a functional linkage between a promoter and a second sequence, wherein the promoter sequence initiates and mediates transcription of the DNA sequence corresponding to the second sequence.
  • operably linked means that the nucleic acid sequences being linked are contiguous and, where necessary to join two protein coding regions, contiguous and in the same reading frame.
  • Transdominant Soluble Tat Peptides are N amino acid residues in length, where N is any of the integers selected from the group consisting of from 1 2 to 300.
  • transdominant soluble Tat peptides are less than 300 amino acids in length, typically less than 200 amino acids in length, preferably, less than 100 or 50 amino acids in length, more preferably less than 40, 30, or 25 amino acids in length, and most preferably less than 20 amino acids but at least 14 amino acids in length.
  • the transdominant soluble Tat peptide comprises a transdominant Tat peptide sequence.
  • the transdominant Tat peptide sequence includes the sequence: Cys-Phe-Xaa 39 -Xaa 40 -Xaa 41 -Gly-Leu-Gly-lle-Ser-Xaa 47 -Gly-Xaa 49 -Lys (SEQ ID NO: 1 ).
  • Xaa 39 is an amino acid residue selected from the group consisting of: Leu, Met, lie, Thr, Gin, and Val;
  • Xaa 40 is an amino acid residue selected from the group consisting of: Thr, Arg, Lys, and Asn;
  • Xaa 41 is an amino acid residue exclusive of Lys;
  • Xaa 47 is an amino acid residue selected from the group consisting of: Tyr and His;
  • Xaa 49 is an amino acid residue selected from the group consisting of: Arg and Lys.
  • HIV-1 Tat protein variants and the consensus sequences of subtypes of the HIV-1 Tat protein can be had by reference to the HIV Sequence Database, T-10, MS K710, (Los Alamos, New Mexico 87545), incorporated herein by reference.
  • the following six groups each contain amino acids that are conservative substitutions for one another:
  • the amino acid residue at position 41 is not a conservative substitution for lysine. In particularly preferred embodiments, the amino acid residue at position 41 is an alanine.
  • the transdominant peptide sequence comprises an amino acid residue at the amino terminal and preceding amino acid residue 37 (i.e., at position 36), wherein amino acid residue 36 is selected from the group consisting of: Leu, Val, Ala, Asn, Met, Trp, and Tyr.
  • the transdominant peptide sequence comprises an amino acid residue substitution at a position selected from the group consisting of: 44, 46, 47, and combinations thereof.
  • the amino acid residue substituted at positions 44, 46, or 47 can be selected from any amino acid other than the one specified in the wild-type Tat sequence for that position.
  • any of the natural amino acids or analogs thereof which differ from the amino acid residues present at position 44 (Gly), 46 (Ser), or 47 (Tyr or His) can be substituted therefor.
  • the substitution is at position 44.
  • the substitution at position 44 is a serine; the substitution at position 46 or 47 is an alanine.
  • the transdominant peptide sequence will be less than 35 amino acid residues in length, typically less than 30, preferably less than 25, and most preferably less than 20 amino acid residues in length.
  • the amino acid sequence which makes up the transdominant soluble Tat peptide and which is linked to the transdominant peptide sequence i.e., the "non-transdominant peptide sequence" will be incapable of transactivating the HIV LTR (long terminal repeat) .
  • the non-transdominant peptide sequence component of the transdominant soluble Tat peptide will not increase transactivation by more than 20% relative to a control lacking the non-transdominant peptide sequence.
  • the non-transdominant peptide sequence generally should not substantially interfere in the transdominant phenotype provided by the transdominant peptide sequence.
  • the non-transdominant peptide sequence should not substantially reduce cell viability (e.g., increase cell doubling time by more than 10%) .
  • the transdominant soluble Tat peptide is soluble in an aqueous solution. Within any of the up to 70 amino acid residues contiguous and extending toward the amino terminal end from amino acid residue 37 of the transdominant peptide sequence, an intact amino-terminal domain and/or an intact cysteine-rich domain is lacking, with one proviso.
  • the proviso is that an amino-terminal domain is directly adjacent and at the amino-terminal end of the cysteine-rich domain.
  • a construct in which the amino-terminal domain and the cysteine-rich domain are situated so they no longer function to transactivate an HIV LTR when fused to, for example, a Tat protein sequence from 37 through 86, is within the scope of the present invention.
  • the transdominant peptide sequence lacks an intact amino-terminal domain lying between the amino acids which precede amino acid residue 37 (cysteine) of the transdominant peptide sequence by between 10 and 50 amino acids; more preferably between 1 6 and 40, most preferably between 1 6 and 36.
  • the transdominant peptide sequence lacks an intact cysteine-rich domain lying within the amino acid residues within 30 amino acid residues contiguous to and preceding the transdominant peptide sequence (e.g., amino acid residue 37) .
  • a cysteine-rich domain is absent within the 20 amino acids contiguous to residue 37 of the transdominant peptide sequence.
  • a cysteine-rich domain is absent within the 1 6 amino acids contiguous to residue 37 of the transdominant peptide sequence. Most preferably, the cysteine-rich domain does not overlap the transdominant peptide sequence at amino acid 37 or reside within the preceding 1 5 contiguous amino acids from amino acid 37.
  • the presence of an amino-terminal domain or a cysteine-rich domain can be identified using expression cassettes in which all of the up to 70 amino acids contiguous and proximal to amino acid residue 36 (inclusive) of the transdominant soluble Tat peptide are fused to amino acids 37 to 86 of a wild- type HIV-1 Tat protein.
  • Transfection and CAT assays for transactivation of the HIV-1 LTR can be determined using methods known to those of skill in the art and as disclosed herein at Example 1 . See, also, Kashanchi et al., J. Virol. , 68(5) :3298-3307 (1 994); Pearson et al., Proc. Natl. Acad. Sci. USA, 87:5079- 5083 (1 990); Frankel et al., Proc. Natl. Acad. Sci. USA 86:7397-7401 ( 1 989) .
  • the fusion protein which lacks either an amino-terminal domain, a cysteine-rich domain, or both, will transactivate the HIV-LTR by less than 20% relative to the wild-type HIV-1 Tat protein control, preferably by less than 1 5%, more preferably by less than 10%, and most preferably by less than 5%.
  • the present invention provides isolated nucleic acids encoding each of the transdominant soluble Tat peptides of the present invention as described more fully, supra.
  • the isolated nucleic acids encoding transdominant soluble Tat peptides can be RNA, DNA, or chimeras thereof.
  • Nucleic acids encoding transdominant soluble Tat peptides can be made using standard recombinant or synthetic techniques. With the amino acid sequences of the transdominant soluble Tat peptides herein provided, one of skill can readily construct a variety of clones containing functionally equivalent nucleic acids, such as nucleic acids which differ in sequence but which encode the same peptides. Cloning methodologies to accomplish these ends, and sequencing methods to verify the sequence of nucleic acids are well known in the art. Examples of appropriate cloning and sequencing techniques, and instructions sufficient to direct persons of skill through many cloning exercises are found in Sambrook, et al., Molecular Cloning: A Laboratory Manual (2nd Ed., Vols.
  • the isolated nucleic acid compositions of this invention can also be synthesized in vitro.
  • Deoxynucleotides can be synthesized chemically according to the solid phase phosphoramidite triester method described by Beaucage and Caruthers ( 1 981 ), Tetrahedron Letts. , 22(20) : 1 859-1862, e.g., using an automated synthesizer, e.g., as described in Needham-VanDevanter et al. ( 1 984) Nucleic Acids Res., 1 2:61 59-61 68.
  • recombinantly engineered cell such as bacteria, yeast, insect (especially employing baculoviral vectors), and mammalian cells.
  • a "recombinant protein” is a protein produced using cells that do not have an endogenous copy of the DNA construct (e.g., a vector) which is able to express the protein. The cells produce the recombinant protein because they have been genetically altered by the introduction of the appropriate nucleic acid sequence.
  • nucleic acids encoding transdominant soluble Tat peptides will typically be achieved by operably linking the DNA to a promoter (which is either constitutive or inducible), followed by incorporation into an expression vector.
  • the vectors can be suitable for replication and integration in either prokaryotes or eukaryotes.
  • Typical expression vectors contain transcription and translation terminators, initiation sequences, and promoters useful for regulation of the expression of the DNA encoding the transdominant soluble Tat peptide.
  • expression vectors which contain, at the minimum, a strong promoter to direct transcription, a ribosome binding site for translational initiation, and a transcription/translation terminator.
  • transdominant soluble Tat peptides of this invention can be purified to substantial purity by standard techniques well known in the art, including selective precipitation with such substances as ammonium sulfate, column chromatography, immunopurification methods, and others. See, for instance, R. Scopes, Protein Purification: Principles and Practice, Springer-Verlag: New York ( 1 982); Deutscher, Guide to Protein Purification, Academic Press, 1990.
  • antibodies may be raised to the transdominant soluble Tat peptides as described herein.
  • the protein may then be isolated from cells expressing the recombinant transdominant soluble Tat peptide and further purified by standard protein chemistry techniques.
  • the present invention also provides methods of inhibiting HIV transcription or translation (i.e., HIV replication) in a mammalian cell, most preferably a primate cell such as macaques, chimpanzees, or human cells.
  • the method comprises administering to a mammalian cell a therapeutically effective amount of a transdominant soluble Tat peptide of the present invention, wherein the therapeutically effective amount is sufficient to inhibit HIV replication.
  • Administration of the transdominant soluble Tat peptide may be accomplished by administering the peptide itself to a mammalian cell, or by expression from a nucleic acid encoding a transdominant soluble Tat peptide of the present invention.
  • the replication of HIV is inhibited by at least 20%, in some embodiments by at least 30%, more often at least 40%, generally, at least 50%, preferably at least 60%, more preferably at least 70%, and most preferably at least 80%.
  • the viral strain whose replication is inhibited is HIV-1 , HIV-2, or SIV.
  • Methods of assessing inhibition of HIV or SIV replication are known to those of ordinary skill in the art. See, e.g., Example 3; and, Kashanchi et al., J. Virol. , 68(5) :3298-3307 ( 1 994) .
  • the transdominant soluble Tat peptides of the present invention can be administered by provision of the transdominant soluble Tat peptide itself, or by expression of a nucleic acid which encodes a transdominant soluble Tat peptide.
  • a therapeutically effective amount of the transdominant Tat peptide is administered under physiological conditions.
  • physiological conditions are those which support cell viability and biosynthesis.
  • physiological conditions also support the proliferation of cells.
  • physiological conditions includes reference to conditions (e.g., temperature, osmolarity, pH) that are typical inside a living organism or a cell. While it is recognized that some organs are subject to extreme conditions, the intra-organismal and intracellular environment normally varies around pH 7 (i.e.
  • transdominant soluble Tat peptides of the present invention contains water as the predominant solvent, and exists at a temperature above 0°C and below 50°C. Osmolarity is within the range that is supportive of cell viability and proliferation.
  • the transdominant soluble Tat peptides of the present invention, and nucleic acids encoding the transdominant soluble Tat peptides of the present invention are useful for parenteral, intravenous, topical, oral, or local administration, such as by aerosol or transdermally, for prophylactic and/or therapeutic treatment of a mammal, particularly a human.
  • the pharmaceutical compositions can be administered in a variety of unit dosage forms depending upon the method of administration.
  • compositions containing the present transdominant soluble Tat peptides can be administered for therapeutic or prophylactic treatments.
  • compositions are administered to a patient suffering from an HIV infection in an amount sufficient to at least partially arrest the disease and its complications.
  • compositions are administered to a patient susceptible to an HIV infection in an amount sufficient to at least inhibit transcription from the HIV LTR, or inhibit translation of a TAR mRNA.
  • An amount adequate to accomplish this is defined as a "therapeutically effective dose.” Amounts effective for this use will depend upon the severity of the disease and the general state of the patient's health. Means of assessing inhibition of HIV replication, transcription, and translation are known to those of skill in the art, and discussed, supra.
  • Single or multiple administrations of the compositions may be administered depending on the dosage and frequency as required and tolerated by the patient. In any event, the composition should provide a sufficient quantity of the peptides or nucleic acids of this invention to effectively treat the patient.
  • Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the packaged nucleic acid suspended in diluents, such as water, saline or PEG 400; (b) capsules, sachets or tablets, each containing a predetermined amount of the active ingredient, as liquids, solids, granules or gelatin; (c) suspensions in an appropriate liquid; and (d) suitable emulsions.
  • liquid solutions such as an effective amount of the packaged nucleic acid suspended in diluents, such as water, saline or PEG 400
  • capsules, sachets or tablets each containing a predetermined amount of the active ingredient, as liquids, solids, granules or gelatin
  • suspensions in an appropriate liquid such as water, saline or PEG 400
  • Tablet forms can include one or more of lactose, sucrose, mannitol, sorbitol, calcium phosphates, corn starch, potato starch, tragacanth, microcrystalline cellulose, acacia, gelatin, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, stearic acid, and other excipients, colorants, fillers, binders, diluents, buffering agents, moistening agents, preservatives, flavoring agents, dyes, disintegrating agents, and pharmaceutically compatible carriers.
  • Lozenge forms can comprise the active ingredient in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the active ingredient, carriers known in the art.
  • a flavor usually sucrose and acacia or tragacanth
  • pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the active ingredient, carriers known in the art.
  • Peptide or nucleic acid compositions of the invention can be made into aerosol formulations (i.e., they can be "nebulized") to be administered via inhalation.
  • Aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.
  • Suitable formulations for rectal administration include, for example, suppositories, which consist of the packaged nucleic acid with a suppository base.
  • Suitable suppository bases include natural or synthetic triglycerides or paraffin hydrocarbons.
  • gelatin rectal capsules which consist of a combination of the packaged nucleic acid with a base, including, for example, liquid triglycerides, polyethylene glycols, and paraffin hydrocarbons.
  • Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives.
  • compositions can be administered, for example, by intravenous infusion, orally, topically, intraperitoneally, intravesically or intrathecally. Parenteral administration and intravenous administration are the preferred methods of administration.
  • the formulations of nucleic acids or peptides of the invention can be presented in unit-dose or multi-dose sealed containers, such as ampules and vials.
  • Injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described .
  • Cells transfected by the nucleic acid as described in the context of ex vivo therapy can also be administered intravenously or parenterally as described infra.
  • Actual methods for preparing parenterally administrable compositions will be known or apparent to those skilled in the art and are described in more detail in such publications as Remington 's Pharmaceutical Science, 1 9th ed ., Mack Publishing Company, Easton, Pennsylvania ( 1 995).
  • transdominant soluble Tat peptides when administered orally, must be protected from digestion. This is typically accomplished either by complexing the peptide with a composition to render it resistant to acidic and enzymatic hydrolysis or by packaging the peptide in an appropriately resistant carrier such as a liposome. Means of protecting proteins from digestion are well known in the art.
  • emulsion based systems have been proposed as pharmaceutical formulations for administration of peptides and proteins.
  • those emulsions may be characterized as water-in-oil microemulsions, which are thermodynamically stable and usually self-emulsifying; see Cho et al. , WO 90/031 64; Cho et al. , WO 91 /14454; Affinity, WO 92/18147; Riley, U.S. Pat. No. 5,055,303; Ritschel, Meth. Find. Exp. Clin. Pharmacol. 1 3:205-220 ( 1 991 ).
  • the internal dispersed phase containing the protein typically is aqueous and the continuous phase typically is lipoidal.
  • Other emulsions have been disclosed in the submicron size range which contain specific ingredients such as lysophosphatidylcholine (Yesair, WO 92/031 21 ) .
  • Zerbe et al. , WO 93/00076 disclose a drug delivery system consisting of a suspension of microparticles having a spherical core composed of a biopolymer, preferably a protein such as albumin or gelatin, which typically has been crosslinked or denatured to maintain its structural coherency.
  • the spherical core can be combined with a bioadhesive polymer.
  • Riley, U.S. Pat. No. 5,055,303 discloses a bioadherent emulsion of the water-in-hydrophobic phase type, wherein the continuous hydrophobic phase is a solid fat.
  • 5,514,670 discloses emulsions which include submicron particles, a peptide, and an aqueous continuous phase that enhances oral bioavailability of the peptide.
  • the aqueous continuous phase promotes absorption of the bioactive peptide through mucosal surfaces by achieving mucoadhesion of the emulsion particles.
  • microspheres WO 93/00077
  • lipospheres Domb, U.S. Pat. No. 5, 1 88,837
  • microcapsules EP 442671
  • liposomes WO 91 /05545
  • other lipid vesicles Yoshida et al. , EP 140,085) .
  • WO 90/031 64 WO 91 /14454
  • WO 92/1 8147 U.S. Patent Nos.
  • the transdominant peptide sequence of the present invention is linked to a targeting ligand which provides selective binding to a desired cell receptor or allows transport into an anatomical site.
  • a targeting ligand which provides selective binding to a desired cell receptor or allows transport into an anatomical site.
  • Targeting ligands selective for T-cells are known in the art. Callebaut et al.
  • TASP template assembled synthetic peptides
  • a lysine-rich short peptide (KKKGPKEKGC (SEQ ID NO:) or KKKKKGC (SEQ ID NO:)) was used as a template to covalently anchor arrays of tripeptides, such as RPR, RPK, or KPR, at the e-amino groups of the lysine residues in the templates using Boc and Fmoc solid-phase methodology.
  • the RP dipeptide present in these arrays is a highly conserved motif in the V3 loop of the extracellular envelope glycoprotein of different types of HIV isolates. This extracellular glycoprotein contains the binding site for the CD4 receptor. Pentavalent presentation of 5(RPR)-, 5(RPK)-, or 5(KPR)-TASP molecules were strongly inhibitory for HIV infection.
  • a transdominant peptide sequence of the present invention can be linked internally, or at the amino or carboxy terminal end of one or more of the peptides in these pentavalent TASP structures to provide targeting to T-cells.
  • one or more amino acids in the TASP molecule and/or in the transdominant peptide sequence are D-amino acid analogs.
  • reduced peptide bond analogs between the amino terminal and penultimate amino terminal amino acids of the TASP peptides and/or the transdominant soluble Tat peptide can be used to increase the antiviral potency of the TASP-transdominant soluble Tat peptide conjugate.
  • Reduced peptide bond analogs are known in the art and can be synthesized by reductive amination of N-Boc- ⁇ -amioaldehydes in dimethylformamide containing 1 % acetic acid .
  • Linkage via peptide bonds or chemical crosslinkers is known in the art. Linker molecules are readily available from commercial sources (Pierce Chemical Company, Rockford Illinois).
  • a "linker”, as used herein, is a molecule that is used to join two molecules.
  • the linker is capable of forming covalent bonds to both molecules.
  • Suitable linkers are well known to those of skill in the art and include, but are not limited to, straight or branched-chain carbon linkers, heterocyclic carbon linkers, or peptide linkers. Where both molecules are poiypeptides, the linkers may be joined to the constituent amino acids through their side groups (e.g. , through a disulfide linkage to cysteine) .
  • chimeric conjugates comprising linkages which are cleavable in the vicinity of the target site may be used when the effector is to be released at the target site. Cleaving of the linkage to release the agent from the ligand may be prompted by enzymatic activity or conditions to which the immunoconjugate is subjected either inside the target cell or in the vicinity of the target site.
  • cleavable linkers are known to those of skill in the art. See U.S. Pat. Nos. 4,61 8,492; 4,542,225, and 4,625,014.
  • the mechanisms for release of an agent from these linker groups include, for example, irradiation of a photolabile bond and acid-catalyzed hydrolysis.
  • U.S. Pat. No. 4,671 ,958, for example, includes a description of immunoconjugates comprising linkers which are cleaved at the target site in vivo by the proteolytic enzymes of the patient's complement system.
  • a transdominant peptide sequence of the present invention is linked to a synthetic polymeric construct (SPC) which includes the consensus sequence of the HIV-1 surface envelope glycoprotein gp1 20 V3 loop (GPGRAF (SEQ ID NO:)) .
  • SPC synthetic polymeric construct
  • GPGRAF SEQ ID NO:
  • peptide chains are elongated stepwise on 4-(oxy-methyl)-phenylacetamidomethyl resins by using t- butyloxycarbonyl-benzyl chemistry.
  • the SPC is constructed using multimeric V3 loop consensus sequences linked to amino groups of lysine residues.
  • [GPGRAF] 8 -SPC is a multibranched structure comprising eight GPGRAF sequences, with each of the GRGRAF sequences linked to an amine group of lysine (K) in the multimeric structure: (K) 4 -(K) 2 -(K)- ?A.
  • the SPC typically includes at least six of the V3 loop consensus sequences, and preferably at least eight of the V3 loop consensus sequences, but less than 100 V3 loops, preferably less than 50, more preferably less than 25, and most preferably less than 1 5.
  • the SPC may be linked to the transdominant peptide sequence at the carboxy terminal amino acid, amino terminal amino acid, or via an internal amino acid . Preferably, linkage is achieved via a peptide bond to the amino terminus of the transdominant peptide sequence.
  • compositions for administration will commonly comprise a solution of the transdominant soluble Tat peptide dissolved in a pharmaceutically acceptable carrier, preferably an aqueous carrier.
  • a pharmaceutically acceptable carrier preferably an aqueous carrier.
  • aqueous carriers can be used, e.g. , buffered saline and the like. These solutions are sterile and generally free of undesirable matter.
  • These compositions may be sterilized by conventional, well known sterilization techniques.
  • the compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like.
  • concentration of these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight and the like in accordance with the particular mode of administration selected and the patient's needs.
  • a typical pharmaceutical composition for intravenous administration would be about 0.1 to 10 mg of peptide per patient per day. Dosages from 0.1 up to about 100 mg per patient per day may be used, particularly when the peptide composition is administered to a secluded site and not into the blood stream, such as into a body cavity or into a lumen of an organ. As will be readily understood by the clinician of ordinary skill in the art, the dose will be dependent upon the properties of the particular peptide employed, e.g. , its activity and biological half-life, the concentration of peptide in the formulation, the site and rate of dosage, the clinical tolerance of the patient involved, the severity of the disease, and the like.
  • Cells can be transfected with a nucleic acid encoding a transdominant soluble Tat peptide of the present invention in vitro and in vivo.
  • transfected includes reference to the introduction of a nucleic acid into a eukaryotic cell where the nucleic acid can be incorporated into the genome of the cell (i.e., chromosome, plasmid, or mitochondrial DNA), converted into an autonomous replicon, or transiently expressed (e.g., transfected mRNA).
  • a variety of methods for delivering and expressing a nucleic acid within a mammalian cell are known to those of ordinary skill in the art. Such methods include, for example liposome-based gene delivery (Debs and Zhu (1993) WO 93/24640; Mannino and Gould-Fogerite (1988) BioTechniques 6(7): 682-691; Rose U.S. Pat No.5,279,833; Brigham (1991) WO 91/06309;
  • a therapeutically effective amount of the peptide is expressed.
  • Such genetic therapy procedures have been used to correct acquired and inherited genetic defects, cancer, and viral infection in a number of contexts.
  • the ability to express artificial nucleic acids in humans facilitates the prevention and/or cure of many important human diseases, including many diseases which are not amenable to treatment by other therapies.
  • in vivo expression of cholesterol-regulating genes genes which selectively block the replication of HIV, and tumor-suppressing genes in human patients dramatically improves the treatment of heart disease, AIDS, and cancer, respectively.
  • a nucleic acid encoding a transdominant soluble Tat peptide of the present invention is operably linked to a promoter which is preferentially induced in HIV infected cells. Accordingly, introduction and induction of this promoter-nucleic acid construct in HIV infected cells directs expression of the nucleic acid encoding a transdominant soluble Tat peptide.
  • Preferred promoters include the VA., promoter (GenBank Accession No. M35961 ) from adenovirus, and the LTR promoter. The sequence of the VA T and LTR promoters are well known in the art and provided below.
  • Delivery of the gene or genetic material into the cell is the first critical step in gene therapy treatment of disease.
  • a large number of delivery methods are well known to those of skill in the art. Such methods include, for example liposome-based gene delivery (Debs and Zhu ( 1 993) WO 93/24640;
  • Widely used retroviral vectors include those based upon murine leukemia virus
  • AAV-based vectors can be used to transfect cells with target nucleic acids, e.g., in the in vitro production of nucleic acids and peptides, and in in vivo and ex vivo gene therapy procedures. See, West et al. (1987) Virology 160:38-47; Carter et al. (1989) U.S. Patent No.4,797,368; Carter et al. WO 93/24641 (1993); Kotin (1994) Human Gene Therapy 5:793-801; Muzyczka (1994) d. Clin.
  • Ex vivo cell transfection for gene therapy (e.g., via re-infusion of the transformed cells into the host organism) is well known to those of skill in the art.
  • cells are isolated from the subject organism, transfected with a nucleic acid encoding a transdominant soluble Tat peptide (alone or in a vector), and re-infused back into the subject organism (e.g., a human patient) .
  • the nucleic acid encoding a transdominant soluble Tat peptide is placed in a vector under the control of an activated or constitutive promoter, or under the control of an inducible promoter.
  • the transfected cell(s) express a therapeutically effective amount of the peptide to inhibit replication of HIV, or to inhibit transcription or translation of HIV nucleic acids.
  • stem cells are used in ex- vivo procedures for cell transfection and gene therapy.
  • the advantage to using stem cells is that they can be differentiated into other cell types in vitro, or can be introduced into a mammal (such as the donor of the cells) where they will engraft in the bone marrow.
  • Methods for differentiating CD34 + cells in vitro into clinically important immune cell types using cytokines such a GM-CSF, IFN- j and TNF- ⁇ are known (see, Inaba et al. ( 1 992) J. Exp. Med. 1 76, 1 693-1 702, and Szabolcs et al. ( 1 995) 1 54: 5851 -5861 ) .
  • Stem cells are isolated for transfection and differentiation using known methods. For example, in mice, bone marrow cells are isolated by sacrificing the mouse and cutting the leg bones with a pair of scissors. Stem cells are isolated from bone marrow cells by panning the bone marrow cells with antibodies which bind unwanted cells, such as CD4 + and CD8 + (T cells), CD45 + (panB cells), GR-1 (granulocytes), and la d (differentiated antigen presenting cells) . For an example of this protocol see, Inaba et al. ( 1 992) J. Exp. Med. 176, 1 693-1 702. In humans, bone marrow aspirations from iliac crests are performed, e.g., under general anesthesia in the operating room.
  • the bone marrow aspirations is approximately 1 ,000 ml in quantity and is collected from the posterior iliac bones and crests. If the total number of cells collected is less than about 2 x 10 8 /kg, a second aspiration using the sternum and anterior iliac crests in addition to posterior crests is performed . During the operation, two units of irradiated packed red cells are administered to replace the volume of marrow taken by the aspiration.
  • Human hematopoietic progenitor and stem cells are characterized by the presence of a CD34 surface membrane antigen. This antigen is used for purification, e.g., on affinity columns which bind CD34.
  • the mononuclear cells are separated from the other components by means of ficol gradient centrifugation. This is performed by a semi-automated method using a cell separator (e.g., a Baxter Fenwal CS3000 + or Terumo machine) .
  • the light density cells composed mostly of mononuclear cells are collected and the cells are incubated in plastic flasks at 37°C for 1 .5 hours.
  • the adherent cells (monocytes, macrophages and B-Cells) are discarded .
  • the non-adherent cells are then collected and incubated with a monoclonal anti-CD34 antibody (e.g., the murine antibody 9C5) at 4°C for 30 minutes with gentle rotation.
  • a monoclonal anti-CD34 antibody e.g., the murine antibody 9C5
  • the final concentration for the anti-CD34 antibody is 10 ⁇ g/ml.
  • paramagnetic microspheres Dynamic Beads, supplied by Baxter Immunotherapy Group, Santa Ana, California coated with sheep antimouse IgG (Fc) antibody are added to the cell suspension at a ratio of 2 cells/bead. After a further incubation period of 30 minutes at 4°C, the rosetted cells with magnetic beads are collected with a magnet.
  • Chymopapain (supplied by Baxter Immunotherapy Group, Santa Ana, California) at a final concentration of 200 U/ml is added to release the beads from the CD34 + cells.
  • an affinity column isolation procedure can be used which binds to CD34, or to antibodies bound to CD34 (see, the examples below) . See, Ho et al. ( 1 995) Stem Cells 1 3 (suppl. 3): 100-105. See also, Brenner ( 1 993) Journal of Hematotherapy 2: 7-1 7.
  • hematopoietic stem cells are isolated from fetal cord blood . Yu et al. ( 1 995) Proc. Natl. Acad. Sci. USA, 92: 699-703 describe a method of transfecting CD34 + cells from human fetal cord blood using retroviral vectors. 2. In vivo Transfection
  • Vectors containing nucleic acids encoding a transdominant soluble Tat peptide can be administered directly to the organism for transfection of cells in vivo, or a nucleic acid of the present invention can be transfected directly (i.e., in the absence of a vector) .
  • Administration is by any of the routes normally used for introducing a molecule into ultimate contact with blood or tissue cells.
  • the nucleic acids are administered in any suitable manner, preferably with pharmaceutically acceptable carriers. Suitable methods of administering such nucleic acids are available and well known to those of skill in the art, and, although more than one route can be used to administer a particular composition, a particular route can often provide a more immediate and more effective reaction than another route.
  • compositions of the present invention are determined in part by the particular composition being administered, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable formulations of pharmaceutical compositions of the present invention as discussed supra.
  • the dose administered to a patient should be sufficient to effect a beneficial therapeutic response in the patient over time.
  • the dose will be determined by the efficacy of the particular vector employed and the condition of the patient, as well as the body weight or surface area of the patient to be treated.
  • the size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects that accompany the administration of a particular vector, or transfected cell type in a particular patient.
  • the physician evaluates circulating plasma levels of the vector, vector toxicities, progression of the disease, and the production of anti-vector antibodies.
  • the dose equivalent of a naked nucleic acid from a vector is from about 1 ⁇ g to 1 00 ⁇ g for a typical 70 kilogram patient, and doses of vectors which include a retroviral particle are calculated to yield an equivalent amount of therapeutic nucleic acid.
  • inhibitors and transfected cells of the present invention can be administered at a rate determined by the LD-50 of the inhibitor, vector, or transfected cell type, and the side-effects of the inhibitor, vector or cell type at various concentrations, as applied to the mass and overall health of the patient. Administration can be accomplished via single or divided doses.
  • blood samples are obtained and saved for analysis. Between 1 X 10 s and 1 X 10 12 transfected cells are infused intravenously over 60-200 minutes. Vital signs and oxygen saturation by pulse oximetry are closely monitored . Blood samples are obtained
  • Leukopheresis, transfection and reinfusion can be repeated are repeated every 2 to 3 months.
  • infusions can be performed on a out-patient basis at the discretion of the clinician. If the reinfusion is given as an outpatient, the participant is monitored for at least 4, and preferably 8 hours following the therapy.
  • Transfected cells are prepared for reinfusion according to established methods. See, Abrahamsen et al. ( 1991 ) J. Clin. Apheresis, 6: 48- 53; Carter et al. ( 1 988) J. Clin. Arpheresis, 4: 1 1 3-1 1 7; Aebersold et al. ( 1988)
  • the cells should number between 1
  • X 10 8 and 1 X 10 12 the growth characteristics of cells vary from patient to patient and from cell type to cell type. About 72 hours prior to reinfusion of the transfected cells, an aliquot is taken for analysis of phenotype, and percentage of cells expressing the transdominant soluble Tat peptide.
  • Example 1 describes the suppression of transcriptional transactivation using soluble Tat peptides.
  • Tat peptide analogs containing various amino acid substitutions, for their ability to inhibit Tat transactivation of the HIV-1 promoter.
  • CEM lymphocytes grown to early- to mid-log phase, were electroporated with the Tat protein ( 1 ⁇ g), Tat core peptide 36-50 (5 ⁇ g) and the HIV-1 LTR-CAT reporter (5 ⁇ g) .
  • the amino acid sequence for the Tat peptides are: Tat 36-50: V-C-F-T-T-K-A-L-G-l-S-Y-G-R-K (SEQ ID NO:2)
  • Tat 36-50 (41 ) V-C-F-T-T-A-A-L-G-l-S-Y-G-R-K (SEQ ID NO:3) Tat 36-50 (44) : V-C-F-T-K-A-L-S-S-Y-G-R-K (SEQ ID N0:4) Tat 36-50 (46) : V-C-F-T-T-K-A-L-G-l-A-Y-G-R-K (SEQ ID NO:5) Tat 36-50 (47) : V-C-F-T-T-K-A-L-G-l-S-A-G-R-K (SEQ ID NO:6) Tat 36-50 (41 /44) : V-C-F-T-T-A-A-L-S-S-Y-G-R-K (SEQ ID NO:7) Tat 36-50 (41 /46) : V-C-F-T-T-A-A-L-S-S-Y-G-R-K (SEQ ID
  • CEM CD4 + lymphocytes 1 2D7 (as well as U1 and HeLa cells described in subsequent examples) were kept at a density of 0.5 to 0.8 x 10 6 cells/ml with media added daily.
  • 5 x 10 6 cells were electroporated with purified peptides, Tat protein and/or 5 ⁇ g of a reporter plasmid .
  • Synthetic Tat peptides were purified by HPLC to 95 percent purity (Peptide Technologies Corporation, Gaithersburg, MD) .
  • Tat peptide, Tat protein, and the reporter HIV LTR-CAT were mixed with cells and electroporated using a cell porater apparatus (Gibco/BRL, Gaithersburg, MD) .
  • Cell mixtures were electroporated at 800 ⁇ F, 230 volts, in RPMI 1 640 media without fetal calf serum. Following electroporation, cells were plated in 10 ml of complete media and samples collected 48 hours later for either CAT assay, p24 Gag antigen capture assay or northern blot analysis. Samples receiving rTNF- ⁇ (R & D System, Minneapolis, MN) after electroporation were collected 48 hours post-treatment for p24 Gag antigen capture assay (ABI, Bethesda, MD) .
  • Tat protein increased HIV-1 LTR-directed gene expression from 2.1 to 95 percent (45-fold). When wild type 36-50 peptide was included in the transfection no apparent drop in transcription activity was observed. This lack of competition between wild type Tat protein and wild type Tat peptide was also apparent when using each of the four single Tat peptide analogs, i.e. Tat 41 , 44, 46, and 47 (each providing less than a 5 % decrease in activity) . In contrast, the Tat peptide analogs with double amino acid substitutions showed varying degrees of ability to inhibit HIV transfection.
  • peptide analog 41 /44 showed suppression of Tat transactivation from 95.7 to 1 .1 percent
  • peptide 41 /46 showed suppression from 95.7% to 5.5 %
  • 41 /47 showed suppression from 95.7% to 1 2% .
  • Tat peptide analogs were effective competitors for wild type Tat protein in downregulating Tat activated transcription.
  • Example 2 describes the effect of Tat peptide analogs on other promoters.
  • basal transcription of the HTLV-I promoter decreased from 1 9 to 1 5.6 and 1 6.4 percent using 1 and 5 ⁇ g of the peptide analog 41 /44.
  • Tat peptide analog 41 /44 decreased Tax ! ( 1 ⁇ g) transactivated transcription approximately two-fold (49.2 to 22.8 percent) .
  • transcription from the CMV promoter was decreased from 1 7.8 to 9.04 and 6.7 percent in the presence of 1 or 5 ⁇ g of Tat peptide analog 41 /44.
  • Example 3 describes the inhibition of viral replication by a Tat peptide analog in latently infected cells induced by Tat or TNF- ⁇ .
  • Tat peptide analog 41 /44 The ability of the Tat peptide analog 41 /44 to inhibit HIV virus replication was tested in U1 cells, transfected as described in Example 1 with varying amounts of Tat protein. Supernatants were collected 48 hours later for p24 antigen capture assay. The U 1 cells contained two integrated copies of the wild type HIV viral genome, but required either exogenous Tat or cytokines to produce viral particles. In the assays, maximum virus production was induced when approximately 2.5 to 5 ⁇ g of Tat protein was added to the cell culture. Consistent with the results obtained above, in comparison to the wild type peptide (5 ⁇ g), Tat peptide analog 41 /44 (5 ⁇ g) inhibited Tat-induced virus production in U 1 cells by approximately 85% when electroporated with 2.5 ⁇ g of Tat protein. In a comparable experiment, the ability of Tat peptide analogs
  • Tat peptide analogs are able to inhibit cytokine-induced HIV-1 replication. The level of inhibition is likely underestimated, since TNF- ⁇ will induce viral replication in a large percentage of cells. Conversely, the electroporated Tat peptide is most likely present in a small percentage of cells.
  • Example 4 describes the effect of Tat analog peptides in a co-cultivation assay. It was of interest to determine whether the level of virus particles produced in the presence of Tat peptide analog 41 /44 was sufficient to initiate a second round of virus replication. This is an important point to consider when designing specific inhibitors for HIV, since detection of p24 or reverse transcriptase in particles is not necessarily an indication of infectious particles. Dimitrov and Martin, Nature, 375: 1 94-1 95 ( 1 994) . To address this question, we utilized co-cultivation assays in which the induced U1 cells were co- cultivated with the parental U937 monocyte cell line. Transfected U 1 cells (5 x 10 6 ) were co-cultivated with the U937 cells 48 hrs after transfection.
  • the co-cultivation assay was initially tested using either a 1 : 1 , 1 :5, or 1 :25 ratio of infected to uninfected cells.
  • a 1 :5 co-cultivation was determined to be the optimal ratio in obtaining the highest viral production within a 2 week period.
  • Cells were co-cultivated in a total of 4 mis for a period of 2 weeks. After the fist week, 2 mis of media cells was removed and 2 mis of fresh media added.
  • Both U937 and CEM cells were seeded at a density of 0.5 x 10 6 cells per culture dish prior to the co-cultivation experiment. Initially, cells were electroporated with either wild type (2.5 ⁇ g) or peptide analog 41 /44 (2.5/vg), along with Tat protein.
  • the p24 antigen capture assays were performed 48 hrs posttransfection on 400 ⁇ aliquots of the infected culture; the remaining cells were used for co-cultivation assays.
  • the results of this experiment demonstrated that the initial inhibition of HIV-1 virus production by the peptide analog 41 /44, was sufficient to inhibit subsequent rounds of virus replication in the co-cultivation assay. Following seven days of co-cultivation, virus production was decreased by 85%. Consistent with the transfection assay data, the wild type core peptide did not inhibit HIV virus replication. Peptides alone, in the absence of Tat protein, did not induce viral replication.
  • Phosphorlmager Molecular Dynamics
  • RNAs including actin, histone H2b, and GAPDH were monitored in cells treated with Tat and peptide analogs. Consistent with the results of the p24 virus replication assays in U 1 cells treated with Tat and the 41 /44 Tat peptide analog, a decrease in the level of HIV-1 viral mRNA was detected. In contrast, no change in the expression of the cellular GAPDH gene was observed .
  • Example 5 describes the inhibition of Tat Binding Protein (TBP) directed transcription of the HIV-1 promoter by the Tat peptide.
  • TBP Tat Binding Protein
  • Gal4-TAT + /TAR " plasmid contains six Gal4 binding sites, followed by the HIV sequence from -31 to + 25. This construct contains no Sp1 sites or a TAR element.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Procédés et compositions destinés à inhiber la réplication du VIH dans une cellule mammaliène. Les compositions peuvent être constituées d'analogues de peptides Tat solubles, ou d'acides nucléiques codant ces analogues, avec effet inhibiteur sur la transactivation de la répétition terminale longue du VIH.
PCT/US1997/017704 1996-10-04 1997-10-02 Inhibition de la replication du vih au moyen d'analogues de peptides tat solubles WO1998014587A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU46632/97A AU4663297A (en) 1996-10-04 1997-10-02 Inhibition of hiv replication using soluble tat peptide analogs
US09/269,991 US6686333B1 (en) 1996-10-04 1997-10-02 Inhibition of HIV replication using soluble Tat peptide analogs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2765896P 1996-10-04 1996-10-04
US60/027,658 1996-10-04

Publications (1)

Publication Number Publication Date
WO1998014587A1 true WO1998014587A1 (fr) 1998-04-09

Family

ID=21839032

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/017704 WO1998014587A1 (fr) 1996-10-04 1997-10-02 Inhibition de la replication du vih au moyen d'analogues de peptides tat solubles

Country Status (2)

Country Link
AU (1) AU4663297A (fr)
WO (1) WO1998014587A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1278534A4 (fr) * 2000-04-28 2004-09-15 Thymon Llc Procedes et compositions visant a compromettre la multiplication du vih-1
JP2007531705A (ja) * 2003-05-20 2007-11-08 セルペップ ソシエテ アノニム 増大した活性および細胞膜親和性を有する修飾抗ウイルス性ペプチド
EP2033655A1 (fr) * 2007-09-04 2009-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation de composés qui inhibent l'interaction EF-Tu-Nucleoline pour prévenir ou traiter la tularémie
US7563437B2 (en) 2005-02-15 2009-07-21 Thymon, Llc Methods and compositions for impairing multiplication of HIV-1
US7691480B1 (en) * 2005-07-08 2010-04-06 Basf Corporation Elastomeric urethane composition
US8309134B2 (en) 2008-10-03 2012-11-13 Southwest Research Institute Modified calcium phosphate nanoparticle formation
US8404850B2 (en) 2008-03-13 2013-03-26 Southwest Research Institute Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
US8722706B2 (en) 2008-08-15 2014-05-13 Southwest Research Institute Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
US8946200B2 (en) 2006-11-02 2015-02-03 Southwest Research Institute Pharmaceutically active nanosuspensions
US9028873B2 (en) 2010-02-08 2015-05-12 Southwest Research Institute Nanoparticles for drug delivery to the central nervous system

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989012461A1 (fr) * 1988-06-16 1989-12-28 St. Louis University Antagonistes de proteines de transactivation virales
WO1990013630A1 (fr) * 1989-05-03 1990-11-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Retrovirus hautement cytopathogenique hiv-ndk, fragments d'adn de ce retrovirus, procede de preparation d'une proteine et/ou enzyme de ce virus et leurs utilisations
EP0614980A1 (fr) * 1993-01-04 1994-09-14 Transgene S.A. Variants trans-dominants TAT du virus de l'immunodéficience humaine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989012461A1 (fr) * 1988-06-16 1989-12-28 St. Louis University Antagonistes de proteines de transactivation virales
WO1990013630A1 (fr) * 1989-05-03 1990-11-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Retrovirus hautement cytopathogenique hiv-ndk, fragments d'adn de ce retrovirus, procede de preparation d'une proteine et/ou enzyme de ce virus et leurs utilisations
EP0614980A1 (fr) * 1993-01-04 1994-09-14 Transgene S.A. Variants trans-dominants TAT du virus de l'immunodéficience humaine

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FRANKEL A D ET AL: "ACTIVITY OF SYNTHETIC PEPTIDES FROM THE TAT PROTEIN OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 86, no. 19, 1 October 1989 (1989-10-01), pages 7397 - 7401, XP000068439 *
GREEN M ET AL: "MUTATIONAL ANALYSIS OF HIV-1 TAT MINIMAL DOMAIN PEPTIDES: IDENTIFICATION OF TRANS-DOMINANT MUTANTS THAT SUPPRESS HIV-LTR-DRIVEN GENE EXPRESSION", CELL, vol. 58, no. 1, 14 July 1989 (1989-07-14), pages 215 - 223, XP000050694 *
PEARSON L ET AL: "A TRANSDOMINANT TAT MUTANT THAT INHIBITS TAT-INDUCED GENE EXPRESSION FROM THE HUMAN IMMUNODEFICIENCY VIRUS LONG TERMINAL REPEAT", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 87, no. 13, 1 July 1990 (1990-07-01), pages 5079 - 5083, XP000137095 *
YAHI N Y ET AL.: "MULTIBRANCHED V3 PEPTIDES INHIBIT HUMAN IMMUNODEFICIENCY VIRUS INFECTION IN HUMAN LYMPHOCYTES AND MACROPHAGES", JOURNAL OF VIROLOGY, vol. 68, 1994, pages 5714 - 5720, XP002056528 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1278534A4 (fr) * 2000-04-28 2004-09-15 Thymon Llc Procedes et compositions visant a compromettre la multiplication du vih-1
JP2007531705A (ja) * 2003-05-20 2007-11-08 セルペップ ソシエテ アノニム 増大した活性および細胞膜親和性を有する修飾抗ウイルス性ペプチド
US7563437B2 (en) 2005-02-15 2009-07-21 Thymon, Llc Methods and compositions for impairing multiplication of HIV-1
US7691480B1 (en) * 2005-07-08 2010-04-06 Basf Corporation Elastomeric urethane composition
US8946200B2 (en) 2006-11-02 2015-02-03 Southwest Research Institute Pharmaceutically active nanosuspensions
EP2033655A1 (fr) * 2007-09-04 2009-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation de composés qui inhibent l'interaction EF-Tu-Nucleoline pour prévenir ou traiter la tularémie
US8404850B2 (en) 2008-03-13 2013-03-26 Southwest Research Institute Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
US8722706B2 (en) 2008-08-15 2014-05-13 Southwest Research Institute Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
US8309134B2 (en) 2008-10-03 2012-11-13 Southwest Research Institute Modified calcium phosphate nanoparticle formation
US9028873B2 (en) 2010-02-08 2015-05-12 Southwest Research Institute Nanoparticles for drug delivery to the central nervous system

Also Published As

Publication number Publication date
AU4663297A (en) 1998-04-24

Similar Documents

Publication Publication Date Title
US10226538B2 (en) Methods and compositions relating to improved lentiviral vectors and their applications
Mahalingam et al. Nuclear import, virion incorporation, and cell cycle arrest/differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr
US9260725B2 (en) Methods and compositions relating to improved lentiviral vector production systems
CN114736272B (zh) 一种优化病毒膜融合抑制剂的方法及广谱抗冠状病毒脂肽和应用
NZ226040A (en) T-cell specific antigens, dna and pharmaceutical compositions
WO1991018010A1 (fr) Inhibition d'infection virale a l'aide de peptides analogues a la molecule-1 d'adhesion intercellulaire et/ou d'analogues de ces peptides
US6686333B1 (en) Inhibition of HIV replication using soluble Tat peptide analogs
Fujinaga et al. Extracellular Nef protein regulates productive HIV-1 infection from latency.
WO1998014587A1 (fr) Inhibition de la replication du vih au moyen d'analogues de peptides tat solubles
WO2018191858A1 (fr) Lipopeptide puissant inhibiteur du vih, dérivé de celui-ci, composition pharmaceutique et utilisation correspondantes
RU2290197C2 (ru) Фармацевтическое средство для лечения вич-инфекции, содержащая его композиция и способы его применения
US20070037249A1 (en) Molecules that block viral infectivity and methods of use thereof
WO1996025492A1 (fr) MUTANTS DU FACTEUR D'INITIATION EUCARYOTE 5A (eIF-5A)
EP0323157A2 (fr) Composés antiviraux et méthodes
WO1993025235A1 (fr) Procedes therapeutiques destines au sida, a base de peptides vpx d'hiv-2
AU721121B2 (en) Inactivation of HIV co-receptors as therapy for HIV infection
WO2000018426A1 (fr) Inducteurs d'apoptose
WO1996034009A1 (fr) Acides nucleiques chimeriques et proteines inhibant l'expression du vih-1
EP1311538B1 (fr) Inhibiteurs de la replication du vih et procedes de traitement d'infections par le vih
AU2003246119A1 (en) Anti-hiv agent
US20060068389A1 (en) Methods and compositions for inhibiting hiv replication
WO2000045833A1 (fr) Systeme de resistance aux medicaments du vih
Agentsa Implications for the Design of Small-Peptide
WO2004106364A1 (fr) Peptides stabilisants et leurs utilisation dans la preparation des inhibiteurs pour stabiliser le vih
CA2150027A1 (fr) Agents therapeutiques contre le sida prepares a partir de peptides ma du vih

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998516838

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09269991

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载